[A18-14] Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2018
Project no.:
A18-14
Commission:
Commission awarded on 20.02.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies
Patients who have responded inadequately to treatment with a conventional DMARD or a bDMARD: added benefit not proven due to lack of data. If first bDMARD treatment is indicated: hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-47 | Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14 | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-65 | Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-16 A G-BA decision was published.